about
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesInteraction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in Alloxan Induced Diabetic MiceFacilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activityGuidelines for Perioperative Management of the Diabetic PatientEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Thiazolidinediones: a new class of antidiabetic drugs.Current therapeutic options in type 2 diabetes mellitus: a practical approachKiller proteases and little strokes--how the things that do not kill you make you stronger.Pharmacotherapy of type 2 diabetes mellitus.Effects of exercise training on mitochondrial function in patients with type 2 diabetes.Effects of current therapeutic interventions on insulin resistance.Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.The role of blood glucose-lowering drugs in the light of the UKPDS. United Kingdom Prospective Diabetes Study.Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort studyGlibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231.Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.Age-related mitochondrial DNA depletion and the impact on pancreatic Beta cell function.A practical scheme for the initial out-patient management of type-2 diabetes mellitus.Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes.Effect of sulfonylureas administered centrally on the blood glucose level in immobilization stress modelIs impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized PatientsPotentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx.Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?Falsification Testing of Instrumental Variables Methods for Comparative Effectiveness ResearchInhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus.Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer.Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.Short-Term High-Fat Diet (HFD) Induced Anxiety-Like Behaviors and Cognitive Impairment Are Improved with Treatment by Glyburide.Standards of care for type 2 diabetes in China.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Uncoupling of Cav1.2 from Ca(2+)-induced Ca(2+) release and SK channel regulation in pancreatic β-cells.Genetic susceptibility to type 2 diabetes and implications for therapy.Current and emerging antiglycaemic pharmacological therapies: the renal perspective.Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.Treatment for childhood type 2 diabetes.
P2860
Q24642503-36347329-F8AD-466E-BEBC-9C5B158055A0Q24649730-62FE9ABF-E646-4EC0-A50C-F6090415B601Q24654782-4127B6F0-834E-441F-954B-5849B573606BQ27012832-DAB8ABC8-22FB-413B-8C50-B378DCAA3948Q28250844-EFD7EA0B-0071-43FF-B348-25E8B631888DQ30249371-3CC16163-6A84-4AB4-860F-3C6301C261B8Q33607634-E51653F0-7240-40F1-8E82-F1549A9A6E3BQ33723387-829B9582-98D5-45EC-8F01-3007514620B9Q33896931-4044096C-0FF2-4ACE-9B00-47B4F60106A3Q33992531-E7671D9D-F3C3-4DA1-94DB-EE226FD8D328Q34023559-C015A6FA-F941-4EC4-8C87-538BBEFB00B3Q34163110-1DCFFED8-2E2D-44AA-BB2A-6C3B465C8FD4Q34163377-7838CB83-438C-41A7-9E55-FA11CF6ACD34Q34164112-3AAB61C5-6D84-4213-9EE2-2F17B10F6EF9Q34257350-C5DD00E9-4C95-456F-A8C5-90870A696A1CQ34545864-CB704467-58A0-47D7-BC8A-9757CBE6E1FEQ34734418-55BEE415-5F27-4E08-B0FF-B7BC3B92DC2FQ34756967-BA87E455-436D-467C-9944-86F2568B3CD2Q35060164-9BCCFE98-AE19-48AE-9643-2CE51F6BE8B4Q35175088-8999EBBF-D0B5-401A-A01D-17632FA5F52FQ35578586-30FB0FF1-F0A1-4D61-BCB4-2D4143D54CA0Q35607945-FCC7FE32-E454-40E1-834B-AE4C92883BFAQ35912987-12E4D4FD-FA51-4F76-A562-AFF38917B53FQ36497769-42BBC1E6-DCC1-4B35-A67C-8430BCB2FF26Q36678584-50FF134D-08FC-4CF7-910F-2C056468713BQ36706682-6EC26EE9-C9DB-4DC4-838B-AD9433D404D6Q36856384-6C59DD0A-F39C-484B-BF67-7F6CD399F128Q36922957-D9E8F260-7B14-488E-8BEC-F4E6BCE5C6C8Q36941721-49924DA1-48E4-4CFE-A873-C39B41D7622DQ37166016-4403BBB3-E679-4E68-92FB-610803A3609AQ37412792-D837A13B-9A39-44AD-B4CE-8E75C1094612Q37588842-130CF3FC-C14C-46DB-9ECF-3A898F599245Q37670109-29FC966B-C57B-49FC-8004-41DAD6E74AA6Q37689851-D96E329C-A779-4008-82EE-30B68A543CB7Q37860396-AEF7A5B6-212F-4974-8982-75C731B35337Q37872358-9A7916C8-EB77-4976-8C42-BCE8881B15C0Q38036773-36074BFB-1E27-4096-86D3-D7E85F63A523Q38110432-0E823619-8DD7-4495-9B5D-11B65464E4C8Q38199526-568694FC-173D-4224-9283-D9B899C2037BQ38208811-B8E1D3B8-E5D6-4B42-B546-63B8774FE2E0
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Sulfonylureas in NIDDM.
@ast
Sulfonylureas in NIDDM.
@en
type
label
Sulfonylureas in NIDDM.
@ast
Sulfonylureas in NIDDM.
@en
prefLabel
Sulfonylureas in NIDDM.
@ast
Sulfonylureas in NIDDM.
@en
P356
P1433
P1476
Sulfonylureas in NIDDM.
@en
P2093
P304
P356
10.2337/DIACARE.15.6.737
P407
P577
1992-06-01T00:00:00Z